Optimal Treatment of Depression and Anxiety in Parkinson's Disease

Pontone, Gregory M.; Mills, Kelly A.

doi:10.1016/j.jagp.2021.02.037

Cited by 38 publications

(58 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Table 2 lists most of the drugs approved by the FDA that are available to treat the non-motor symptoms of PD related to depression and anxiety, excessive drooling, and gastrointestinal problems [79][80][81][82][83]. Depression occurs in up to 50% of PwP at some point during the disorder [84]. PwP with depression are typically treated with a standard antidepressant from the class of SSRIs, SNRIs, and other similar neurotransmitter reuptake inhibitors (Table 2).…”

Section: Therapy Options For Treating Non-motor Symptoms Of Pdmentioning

confidence: 99%

“…PwP with depression are typically treated with a standard antidepressant from the class of SSRIs, SNRIs, and other similar neurotransmitter reuptake inhibitors (Table 2). Anxiety in PD takes many forms but is generally described as feelings of worry, panic, unease, and jitteriness [84]. Besides psychotherapy, medication options include SSRIs, and Buspirone appears to deal with generalized anxiety effectively.…”

Section: Therapy Options For Treating Non-motor Symptoms Of Pdmentioning

confidence: 99%

See 1 more Smart Citation

Treatment Options for Motor and Non-Motor Symptoms of Parkinson’s Disease

Church

2021

Biomolecules

133

View full text Add to dashboard Cite

Parkinson’s disease (PD) usually presents in older adults and typically has both motor and non-motor dysfunctions. PD is a progressive neurodegenerative disorder resulting from dopaminergic neuronal cell loss in the mid-brain substantia nigra pars compacta region. Outlined here is an integrative medicine and health strategy that highlights five treatment options for people with Parkinson’s (PwP): rehabilitate, therapy, restorative, maintenance, and surgery. Rehabilitating begins following the diagnosis and throughout any additional treatment processes, especially vis-à-vis consulting with physical, occupational, and/or speech pathology therapist(s). Therapy uses daily administration of either the dopamine precursor levodopa (with carbidopa) or a dopamine agonist, compounds that preserve residual dopamine, and other specific motor/non-motor-related compounds. Restorative uses strenuous aerobic exercise programs that can be neuroprotective. Maintenance uses complementary and alternative medicine substances that potentially support and protect the brain microenvironment. Finally, surgery, including deep brain stimulation, is pursued when PwP fail to respond positively to other treatment options. There is currently no cure for PD. In conclusion, the best strategy for treating PD is to hope to slow disorder progression and strive to achieve stability with neuroprotection. The ultimate goal of any management program is to improve the quality-of-life for a person with Parkinson’s disease.

show abstract

Section: Therapy Options For Treating Non-motor Symptoms Of Pdmentioning

confidence: 99%

Section: Therapy Options For Treating Non-motor Symptoms Of Pdmentioning

confidence: 99%

Treatment Options for Motor and Non-Motor Symptoms of Parkinson’s Disease

Church

2021

Biomolecules

133

View full text Add to dashboard Cite

show abstract

“…The Spectrum of Psychiatric Disorders in PD and the Clinical Utility of the SCL-90-R Psychiatric disorders, particularly depression and anxiety, are part of non-motor symptoms of PD and are highly prevalent in this clinical population. [59][60][61][62][63] Psychiatric disturbances represent a significant source of suffering 64 that is so subjective that, as Parloff et al 36 noted, no one can judge it but the patient. The SCL-90-R and its subscales are easy-to-use and no-time consuming clinimetric indices that can be used not only to detect vulnerability to depression and anxiety in patients with PD but also to support clinicians in the process of assessment of this subjective state of distress.…”

Section: Discussionmentioning

confidence: 99%

The Hopkins Symptom Checklist (SCL-90-R): A Patient-Reported Outcome Measure in Parkinson’s Disease

Carrozzino

Christensen

Patierno

et al. 2021

J Geriatr Psychiatry Neurol

View full text Add to dashboard Cite

Objective: This is the first study applying Clinimetric Patient-Reported Outcome Measures (CLIPROM) criteria to evaluate the construct validity, sensitivity, and clinical utility of the SCL-90-R in patients with Parkinson’s disease (PD). Methods: A Rasch analysis was conducted using a sample of 488 PD outpatients. Results: Testing for dimensionality revealed that less than 5% of t-tests were significant, indicating that the SCL-90-R subscales entailed the property of construct validity. As to the total score, a Person Separation Reliability Index of .96 was found. Conclusions: The SCL-90-R total score is a sensitive screening measure that can be used not only to differentiate healthy stress reactions from symptoms of psychological distress but also to detect PD patients with an increased risk for psychiatric complications. As to the subscales, the brief versions that did not include misfitting items should be used to assess the severity of specific symptoms of psychological distress affecting PD patients.

show abstract

“…Pontone u. Mills (2021) weisen auf die Wirksamkeit verschiedener Antidepressiva und auch der kognitiven Verhaltenstherapie hin, bemängeln jedoch das Fehlen von Daten bezüglich entsprechender Wiedererkrankungsraten und auch potenzieller antidepressiver Augmentationsstrategien [6].…”

Section: Depression Und Parkinson-erkrankung Depression and Parkinson...unclassified

Depression und Parkinson-Erkrankung

Schmauß¹

2022

Fortschr Neurol Psychiatr

View full text Add to dashboard Cite

Depression und Parkinson-Syndrom treten häufig gemeinsam auf 1. Depressive Episoden tragen signifikant zur Morbidität der Parkinson-Erkrankung und damit auch zur Inanspruchnahme der Angehörigen bei. Bei Verwendung moderner Klassifikationssysteme gibt die Mehrzahl der Autoren Prävalenzraten von bis zu 50% an 2. Diese Komorbidität wird immer noch zu selten diagnostiziert und viel zu selten behandelt 1. Hierbei ist zu berücksichtigen, dass depressive Syndrome nicht nur als Reaktion auf die Parkinson-Erkrankung zu interpretieren sind, da sie häufig bereits in der präsymptomatischen Phase der Parkinson-Erkrankung zu beobachten sind und auch bei deutlicher Besserung der Parkinson-Symptomatik unter entsprechender Medikation häufig sistieren.

show abstract

Optimal Treatment of Depression and Anxiety in Parkinson's Disease

Cited by 38 publications

References 53 publications

Treatment Options for Motor and Non-Motor Symptoms of Parkinson’s Disease

Treatment Options for Motor and Non-Motor Symptoms of Parkinson’s Disease

The Hopkins Symptom Checklist (SCL-90-R): A Patient-Reported Outcome Measure in Parkinson’s Disease

Depression und Parkinson-Erkrankung

Contact Info

Product

Resources

About